clinic trial show remdesivir acceler recoveri advanc covid patient world chinadaili com cn sign post gilead scienc headquart april foster citi california photo agenc washington hospit patient advanc covid lung involv receiv remdesivir recov faster similar patient receiv placebo accord releas u s nation institut allergi infecti diseas niaid wednesday result came preliminari data analysi random control trial involv patient began feb preliminari result indic patient receiv remdesivir percent faster time recoveri receiv placebo accord releas specif median time recoveri day patient treat remdesivir compar day receiv placebo result suggest surviv benefit mortal rate percent group receiv remdesivir versu percent placebo group independ data safeti monitor board overse trial met april review data share interim analysi studi team base review data board member note remdesivir better placebo perspect primari endpoint patient time recoveri metric use influenza trial particip trial american repatri quarantin diamond princess cruis ship dock yokohama japan patient volunt particip studi studi site univers nebraska medic center februari accord niaid total site ultim join studi unit state countri europ asia trial sponsor niaid nation institut health clinic trial launch unit state evalu experiment treatment covid gilead scienc american biopharmaceut compani announc preliminari result phase trial remdesivir patient sever covid show half patient day day treatment group discharg hospit week trial evalu day day dose durat remdesivir hospit patient sever covid studi demonstr patient receiv day treatment cours remdesivir achiev similar improv clinic statu compar take day treatment cours accord gilead scienc day percent patient day treatment group percent patient day treatment group achiev clinic recoveri compani said statement new safeti signal identifi remdesivir treatment group gilead initi phase clinic studi evalu safeti efficaci remdesivir adult diagnos covid random open-label multicent studi began enrol patient march enrol total approxim patient initi phase studi countri high preval covid accord gilead